Clinical trials: Dermatologic Diseases
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Acne
Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
The aim of this study is to evaluate, at different times, the RV3278A - ET0943 cosmetic product efficacy after 8 weeks of application on the face (twice-daily application).
- Trial name
- NCT04873089
- Testing
- Cosmetic product
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Breast Neoplasms
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of breast cancer.
- Trial name
- NCT05054010
- Where
- Italy
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Impetigo
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Trial name
- NCT00133848
- Testing
- SB-275833 ointment, 1%
- Where
- 22 sites in India, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- GlaxoSmithKline
Psoriasis
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
This is a randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm®, in 200 adults with moderate to severe plaque type psoriasis who are…
- Trial name
- PRIME (NCT02474082)
- Testing
- Secukinumab, Fumaric acid
- Where
- 32 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
Diabetic Foot Ulcer
Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Diabetic Foot Ulcers
This is a prospective case series evaluating the efficacy and safety of NeoThelium FT Amnion Skin Graft in the Mangement of Diabetic Foot Ulcers
- Trial name
- NCT07039396
- Testing
- NeoThelium FT (HCT/P 361)
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- NuScience Medical Biologics, LLC
Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with…
- Conditions
- Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Breast
- Trial name
- NCT02565758
- Testing
- ABBV-085
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Breast Cancer
Combination Chemotherapy for Metastatic Breast Cancer
The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer
- Trial name
- NCT00191815
- Testing
- Gemcitabine, cisplatin
- Where
- 2 sites in Germany, Russia
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Actinic Keratoses
Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
This study was to be conducted as a multi-centre, randomized, investigator-blinded, active and vehicle-controlled, intra-individual (split-face/scalp) non-inferiority (regarding efficacy) and superiority (regarding pain) study.
- Trial name
- COMET2 (NCT01821391)
- Testing
- NDL-PDT, c-PDT
- Where
- 18 sites in France, Germany and 3 more
- Volunteers
- 131 people
- Sponsor
- Galderma R&D
Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population.
- Conditions
- Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
- Trial name
- REVIVE (NCT06917690)
- Testing
- Oleogel-S10
- Where
- 6 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Psoriasis
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
- Trial name
- NCT00808223
- Testing
- alefacept
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Psoriasis
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.
- Trial name
- NCT00293891
- Testing
- Tacrolimus Cream
- Where
- 33 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- Astellas Pharma Inc
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Generalized Pustular Psoriasis
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-2 (NCT05366855)
- Testing
- Double-blind 200 mg imsidolimab, Open-label 200 mg imsidolimab, Standard of Care (SOC)
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.